Mylan, like other generic drugmakers, feels the pricing pain
Mylan's second-quarter profit and revenue surged, but not as much as Wall Street had expected and the company is taking a more conservative view going forward because of "ongoing challenges and the uncertain U.S. regulatory ...
Aug 9, 2017
0
0